{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:46:13Z","timestamp":1767836773668,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.prp.2022.154293","type":"journal-article","created":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T20:59:30Z","timestamp":1672174770000},"page":"154293","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance"],"prefix":"10.1016","volume":"241","author":[{"given":"Fatma MKh","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duaa S.","family":"Helal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rania N.","family":"Abd-Ellatif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asmaa M.","family":"Elkady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ragia","family":"Sharshar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma","family":"Gharib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abo Elnasr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina M.","family":"El-Guindy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2022.154293_bib1","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2022.154293_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.01044","article-title":"EMT-mediated acquired EGFR-TKI resistance in NSCLC: mechanisms and strategies","volume":"9","author":"Zhu","year":"2019","journal-title":"Front. Oncol."},{"issue":"2014)","key":"10.1016\/j.prp.2022.154293_bib3","article-title":"Annexin A2: its molecular regulation and cellular expression in cancer development","author":"Wang","year":"2014","journal-title":"Dis. Markers"},{"key":"10.1016\/j.prp.2022.154293_bib4","first-page":"5","article-title":"Annexin A2 and cancer: a systematic review","volume":"52","author":"Christensen","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2022.154293_bib5","doi-asserted-by":"crossref","first-page":"30975","DOI":"10.18632\/oncotarget.5199","article-title":"Anxa2 binds to STAT3 and promotes epithelial to mesenchymal transition in breast cancer cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.154293_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12307-011-0064-9","article-title":"The role of annexin A2 in tumorigenesis and cancer progression","volume":"4","author":"Lokman","year":"2011","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.prp.2022.154293_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13050987","article-title":"Cancer-associated fibroblasts as a common orchestrator of therapy resistance in lung and pancreatic cancer","volume":"13","author":"Domen","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2022.154293_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-0994-2","article-title":"Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance","volume":"18","author":"Fiori","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.lungcan.2019.07.020","article-title":"Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer","volume":"135","author":"Alcaraz","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2020.12296","article-title":"Role of cancer-associated fibroblasts in the resistance to antitumor therapy, and their potential therapeutic mechanisms in non-small cell lung cancer (Review)","volume":"21","author":"Chen","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2022.154293_bib11","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1158\/1535-7163.MCT-17-0148","article-title":"JAK1\/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non\u2013small cell lung cancer","volume":"16","author":"Shien","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"2016","key":"10.1016\/j.prp.2022.154293_bib12","article-title":"Annexin A2 coordinates STAT3 to regulate the invasion and migration of colorectal cancer cells in vitro","author":"Xiu","year":"2016","journal-title":"Gastroenterol. Res. Pract."},{"key":"10.1016\/j.prp.2022.154293_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-29703-0","article-title":"Annexin A2 overexpression associates with colorectal cancer invasiveness and TGF-\u00df induced epithelial mesenchymal transition via Src\/ANXA2\/STAT3","volume":"8","author":"Rocha","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2022.154293_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bbcan.2018.10.003","article-title":"EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer","volume":"1871","author":"Tulchinsky","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib15","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2022.154293_bib16","doi-asserted-by":"crossref","first-page":"645","DOI":"10.5858\/arpa.2017-0245-RA","article-title":"Eighth edition staging of thoracic malignancies: implications for the reporting pathologist","volume":"142","author":"Nicholson","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2022.154293_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-017-0594-1","article-title":"Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells","volume":"36","author":"Feng","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2022.154293_bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4103\/EGJP.EGJP_12_19","article-title":"Cancer-associated fibroblasts in epithelial ovarian carcinoma: relation to clinicopathologic characteristics and microvessel density","volume":"39","author":"Abdel Kerim","year":"2019","journal-title":"Egypt. J. Pathol."},{"key":"10.1016\/j.prp.2022.154293_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.prp.2022.154293_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1 \u2013 update and clarification: from the RECIST Committees","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib21","doi-asserted-by":"crossref","first-page":"43411","DOI":"10.1074\/jbc.M408078200","article-title":"An annexin 2 phosphorylation switch mediates p11-dependent translocation of annexin 2 to the cell surface","volume":"279","author":"Deora","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2022.154293_bib22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s13277-013-0715-1","article-title":"Clinical significance of annexin II expression in human non-small cell lung cancer","volume":"34","author":"Jia","year":"2013","journal-title":"Tumor Biol."},{"key":"10.1016\/j.prp.2022.154293_bib23","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1007\/s12094-013-1028-y","article-title":"Prognostic significance of annexin II expression in non-small cell lung cancer","volume":"15","author":"Luo","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.prp.2022.154293_bib24","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yexmp.2006.03.003","article-title":"Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression","volume":"81","author":"Sharma","year":"2006","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.prp.2022.154293_bib25","doi-asserted-by":"crossref","first-page":"106405","DOI":"10.18632\/oncotarget.22433","article-title":"Stromal Annexin A2 expression is predictive of decreased survival in pancreatic cancer","volume":"8","author":"Murphy","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.154293_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2012.04.005","article-title":"Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy","volume":"126","author":"Jin","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.prp.2022.154293_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.trsl.2016.02.002","article-title":"Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome","volume":"171","author":"Lokman","year":"2016","journal-title":"Transl. Res."},{"key":"10.1016\/j.prp.2022.154293_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1002\/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J","article-title":"Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma","volume":"92","author":"Emoto","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib29","article-title":"Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer","volume":"6","author":"Zheng","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2022.154293_bib30","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/path.1935","article-title":"Tenascin C and annexin II expression in the process of pancreatic carcinogenesis","volume":"208","author":"Esposito","year":"2006","journal-title":"J. Pathol."},{"key":"10.1016\/j.prp.2022.154293_bib31","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1007\/s13277-014-1908-y","article-title":"Transforming growth factor-\u03b21 and \u03b1-smooth muscle actin in stromal fibroblasts are associated with a poor prognosis in patients with clinical stage I-IIIA nonsmall cell lung cancer after curative resection","volume":"35","author":"Chen","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.prp.2022.154293_bib32","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/1759-7714.13248","article-title":"Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I\u2013III NSCLC","volume":"11","author":"Schulze","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.prp.2022.154293_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0134965","article-title":"Cancer associated fibroblasts in stage I-IIIA NSCLC: Prognostic impact and their correlations with tumor molecular markers","volume":"10","author":"Kilvaer","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2022.154293_bib34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbadis.2017.12.021","article-title":"Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF\/IGF-1\/ANXA2 signaling","volume":"1864","author":"Yi","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.prp.2022.154293_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1158\/1541-7786.MCR-13-0469","article-title":"CAF-secreted Annexin A1 induces prostate cancer cells to gain stem cell-like features","volume":"12","author":"Geary","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2022.154293_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-020-00916-7","article-title":"Annexin A2-STAT3-Oncostatin M receptor axis drives phenotypic and mesenchymal changes in glioblastoma","volume":"8","author":"Matsumoto","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.prp.2022.154293_bib37","doi-asserted-by":"crossref","first-page":"76116","DOI":"10.18632\/oncotarget.18814","article-title":"Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6\/STAT3 signaling pathway","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2022.154293_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtho.2016.09.003","article-title":"Primary double-strike therapy for cancers to overcome egfr kinase inhibitor resistance: proposal from the bench","volume":"12","author":"Suda","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.prp.2022.154293_bib39","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1080\/09168451.2018.1484275","article-title":"ANXA2 could act as a moderator of EGFR-directed therapy resistance in triple negative breast cancer","volume":"82","author":"Zhang","year":"2018","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.prp.2022.154293_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/ba62ae01-bf71-46c1-a45c-32692d3bb4ab","article-title":"Reciprocal regulation of Annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer","volume":"7","author":"Shetty","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2022.154293_bib41","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1541-7786.MCR-09-0460","article-title":"Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs","volume":"8","author":"Mink","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.prp.2022.154293_bib42","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.2147\/OTT.S89659","article-title":"Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition","volume":"8","author":"Choe","year":"2015","journal-title":"Onco Targets Ther."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822005374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033822005374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:58:58Z","timestamp":1759733938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033822005374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"alternative-id":["S0344033822005374"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2022.154293","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: Implication in epithelial-mesenchymal transition and gefitinib resistance","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2022.154293","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154293"}}